z-logo
open-access-imgOpen Access
Treatment of Multi-Drug Resistant Gram-Negative Bacterial Pathogenic Infections
Author(s) -
Wardah Mohammad Akram,
Godfred Antony Menezes,
Nida Abbas,
Wasim Ahmad,
Ahmed Mohamed Ahmed
Publication year - 2020
Publication title -
journal of pure and applied microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.149
H-Index - 16
eISSN - 2581-690X
pISSN - 0973-7510
DOI - 10.22207/jpam.14.3.02
Subject(s) - acinetobacter baumannii , pseudomonas aeruginosa , antibiotics , medicine , drug resistance , antibiotic resistance , antimicrobial stewardship , intensive care medicine , antimicrobial , tazobactam , ceftazidime/avibactam , microbiology and biotechnology , ceftazidime , biology , bacteria , imipenem , genetics
The multidrug-resistant Gram-negative bacteria (MDR-GNB) infections in severely infected patients present numerous difficulties in terms of treatment failure where antibiotics cannot arrest such drug resistant bacteria. Based on the patient’s medical history and updated microbiological epidemiology data, an effective empirical treatment remains critical for optimal results to safeguard human health. The aim of this manuscript is to review management of MDR-Gram negative pathogenic bacterial infections. Quick diagnosis and narrow antimicrobial spectrum require rapid and timely diagnosis and effective laboratories in accordance with antimicrobial stewardship (AS) principles. Worldwide, there is an increased emergence of Carbapenem-resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa, and Acinetobacter baumannii. Recently, novel therapeutic options, such as meropenem/vaborbactam, ceftazidime/avibactam, ceftolozane/tazobactam, eravacycline and plazomicin became accessible to effectively counteract severe infections. Optimally using these delays the emergence of resistance to novel therapeutic agents. Further study is required, however, due to uncertainties in pharmacokinetic/ pharmacodynamics optimization of dosages and therapeutic duration in severely ill patients. The novel agents should be verified for (i) action on carbapenem resistant Acinetobacter baumannii; (ii) action on CRE of β-lactam/β-lactamase inhibitors dependence on type of carbapenemase; (iii) emergence of resistance to novel antibacterials and dismiss selective pressure promoting development of resistance. Alternative treatments should be approached alike phage therapy or antibacterial peptides. The choice of empirical therapy is complicated by antibiotic resistance and can be combated by accurate antibiotic and their combinations usage, which is critical to patient survival. Noteworthy are local epidemiology, effective teamwork and antibiotic stewardship to guarantee that medications are utilized properly to counter the resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom